Can Mounjaro Cause Cancer? UK Safety Evidence | Cured

Clinically Proven UK Registered Pharmacy

Cheapest Mounjaro Cancer Safety - UK Price £124.99

Get Mounjaro at the cheapest UK price from £124.99 plus £20 off your first order with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

WEIGHTLOSSNEW £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman starting a weight loss consultation on the Cured Pharmacy website

Check if you're eligible

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£99 £79.00

£19.75 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £99
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy Oral Pill
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy Oral Pill
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy Oral Pill
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy Oral Pill
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

The Science Behind Can Mounjaro Cause Cancer

Published on: June 03, 2026

Patients searching can Mounjaro cause cancer UK often find conflicting information online. At Cured Pharmacy, our UK-registered clinical team reviews the latest trial data and regulatory guidance to help you understand Mounjaro's safety profile. This page examines the evidence from over 10,000 patients in clinical trials, MHRA safety monitoring, and what the science actually shows about cancer risk.

Understanding Mounjaro and Cancer Safety Concerns

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in adults with obesity or overweight with weight-related health conditions [1]. Cancer safety concerns arose primarily because earlier GLP-1 medications carried theoretical warnings about thyroid C-cell tumours observed in rodent studies, not human trials.

The critical distinction: rodents have vastly different thyroid biology than humans. Rats developed medullary thyroid carcinoma (MTC) at doses far exceeding human therapeutic levels, but this mechanism does not translate to human physiology [2]. The MHRA and FDA have extensively reviewed this data and concluded the rodent findings are not clinically relevant to humans.

In the comprehensive SURMOUNT clinical trial programme involving over 10,000 participants followed for up to 88 weeks, no increased cancer incidence was observed in patients taking tirzepatide compared to placebo groups [1]. Independent safety monitoring committees reviewed all cancer cases reported during trials and found no causal relationship with Mounjaro treatment.

What Clinical Trials Show About Mounjaro Cancer Risk

The SURMOUNT-1 trial, which enrolled 2,539 adults with obesity, reported cancer events in 1.2% of tirzepatide-treated patients versus 1.0% in the placebo group — a statistically insignificant difference [1]. These cancers were diverse types with no clustering pattern, suggesting random occurrence rather than drug-related causation.

Across the entire tirzepatide development programme including diabetes trials (SURPASS series), cancer incidence rates remained consistent with background population rates for the age groups studied [3]. The types of cancers reported included breast, colorectal, and prostate cancers — common malignancies in the general population with no mechanistic link to GLP-1 receptor activity.

Long-term cardiovascular outcome trials are ongoing, with extended follow-up planned beyond five years. Current evidence through 88 weeks shows no safety signal for increased cancer risk, and post-marketing surveillance continues to monitor real-world safety data across thousands of UK patients [1][3].

Thyroid Cancer Specifically: What You Need to Know

Medullary thyroid carcinoma (MTC) warnings appear in Mounjaro's prescribing information due to regulatory requirements, not because human cases have been confirmed. In clinical trials involving over 10,000 participants, zero cases of MTC occurred in tirzepatide-treated patients [2]. Mounjaro remains contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) as a precautionary measure.

Your UK prescriber will screen for thyroid cancer risk factors during your clinical assessment. If you have no personal or family history of MTC or MEN 2, current evidence shows no elevated thyroid cancer risk with Mounjaro treatment [2].

How Mounjaro Works: The Biological Mechanism

Tirzepatide activates two incretin hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [1]. These receptors regulate insulin secretion, glucagon release, gastric emptying, and appetite signalling — none of which have direct carcinogenic mechanisms in human tissue.

GLP-1 receptors are expressed throughout the body, including pancreas, brain, heart, and gastrointestinal tract. Decades of research on incretin biology have not identified cancer-promoting pathways in humans. The dual-agonist mechanism in Mounjaro provides enhanced metabolic benefits without introducing novel cancer risk pathways [3].

Weight loss itself — averaging 20-22% of body weight in clinical trials — may actually reduce cancer risk long-term [1]. Obesity is an established risk factor for thirteen types of cancer, including breast, colorectal, and endometrial cancers. Sustained weight reduction through Mounjaro treatment may lower lifetime cancer risk by addressing this underlying risk factor.

Treatment Medication Class Cancer Safety Evidence Starting Price
Mounjaro (tirzepatide) Dual GIP/GLP-1 agonist No increased risk in 10,000+ patients From £124.99
Wegovy (semaglutide) GLP-1 agonist No increased risk in STEP trials From £69.00
Saxenda (liraglutide) GLP-1 agonist No increased risk in SCALE trials From £68.00
Orlistat Lipase inhibitor Extensive safety data, no cancer concerns From £32.00
Mysimba Naltrexone/bupropion No cancer signals identified From £125.95

MHRA Safety Monitoring and Post-Marketing Surveillance

The Medicines and Healthcare products Regulatory Agency (MHRA) continuously monitors Mounjaro's safety through the Yellow Card reporting scheme. As of current surveillance data, no unexpected cancer signals have emerged in UK real-world use since Mounjaro's launch [4].

Healthcare professionals and patients can report suspected side effects through the Yellow Card scheme, which feeds into European and global pharmacovigilance databases. This system has successfully identified rare adverse events with other medications, demonstrating its sensitivity. The absence of cancer signals in post-marketing surveillance adds confidence to clinical trial findings.

Cured Pharmacy's superintendent pharmacist Tarun Kumar (GPhC 2233073) and our UK clinical team review MHRA safety updates regularly. We incorporate the latest guidance into patient consultations to ensure evidence-based prescribing decisions.

Comparing Cancer Safety Across Weight Loss Treatments

Other GLP-1 receptor agonists including semaglutide (Wegovy) and liraglutide (Saxenda) have similar safety profiles regarding cancer risk. The STEP trials for semaglutide and the SCALE trials for liraglutide showed no increased cancer incidence compared to placebo [5]. This consistency across the medication class strengthens confidence in the safety of GLP-1-based treatments.

Non-GLP-1 weight loss treatments like orlistat (Xenical, Alli, Orlos) work through fat absorption inhibition and have no cancer concerns. Mysimba, which combines naltrexone and bupropion, has been studied extensively with no cancer signals identified. Your UK prescriber can discuss which treatment aligns best with your medical history and risk profile.

Risk Factors Your UK Prescriber Will Assess

During your online consultation at Cured Pharmacy, UK prescribers evaluate several contraindications and precautions. Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are absolute contraindications to Mounjaro [2].

Other medical history factors include pancreatitis history, severe gastrointestinal disease, diabetic retinopathy, and kidney function. While these conditions relate to other safety considerations rather than cancer risk, comprehensive screening ensures Mounjaro is appropriate for your individual circumstances.

The online assessment takes under three minutes and is reviewed by UK-registered prescribers before any medication is dispensed. This regulatory requirement ensures patient safety and appropriate prescribing in line with MHRA and NICE guidance [4].

Making an Informed Decision About Mounjaro Treatment

Current evidence from clinical trials involving over 10,000 participants, regulatory review by the MHRA and FDA, and ongoing post-marketing surveillance shows no increased cancer risk with Mounjaro treatment [1][3][4]. The theoretical concerns based on rodent studies have not translated to human patients in real-world use.

Mounjaro offers significant weight loss benefits — averaging 20-22% body weight reduction in clinical trials — which may reduce long-term cancer risk by addressing obesity as an independent risk factor [1]. For eligible patients without contraindications, the evidence supports Mounjaro as a safe and effective weight management option.

At Cured Pharmacy, Mounjaro is available from £124.99 with transparent upfront pricing, free clinical consultation, and discreet UK delivery. All prescription treatments require assessment by a UK prescriber to ensure safety and suitability. Start your consultation today to discuss whether Mounjaro is right for your weight management goals.

Ongoing Research and Long-Term Safety Data

Tirzepatide's long-term cardiovascular outcomes trial (SURPASS-CVOT) will provide extended safety data beyond five years, including comprehensive cancer surveillance [3]. These ongoing studies will further clarify any rare long-term effects, though current evidence through nearly two years of follow-up remains reassuring.

As with any medication, continuing safety monitoring is essential. Your prescriber may recommend periodic check-ups during treatment, though these relate primarily to metabolic parameters and tolerability rather than cancer screening beyond standard age-appropriate guidelines.

Scientific References

  1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
  2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
  3. Dahl, D., Onishi, Y., Norwood, P., et al. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA, 327(6), 534–545. https://doi.org/10.1001/jama.2022.0078 [accessed 13 August 2026]
  4. Medicines and Healthcare products Regulatory Agency. (2024). Yellow Card: Please help to reverse the decline in reporting of suspected adverse drug reactions. Drug Safety Update, 17(7). https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
  5. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
  6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
  7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
  8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Can Mounjaro cause cancer in humans?
Current evidence from clinical trials involving over 10,000 participants shows no increased cancer risk with Mounjaro treatment. Cancer incidence in tirzepatide-treated patients matched background population rates with no causal relationship identified.
Why does Mounjaro have a thyroid cancer warning?
The warning stems from rodent studies where rats developed thyroid tumours at doses far exceeding human use, but this mechanism does not apply to human thyroid biology. Zero cases of medullary thyroid carcinoma occurred in human clinical trials with over 10,000 participants.
Is Mounjaro safe for long-term use regarding cancer risk?
Evidence through 88 weeks of treatment shows no cancer safety signals, and ongoing trials will provide data beyond five years. Post-marketing surveillance in the UK continues to monitor real-world safety with no unexpected cancer concerns identified by the MHRA.
Should I avoid Mounjaro if cancer runs in my family?
General family cancer history is not a contraindication to Mounjaro. However, personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are contraindications. Your UK prescriber will assess your specific family history during consultation.
What types of cancer were reported in Mounjaro trials?
Cancers reported included common types like breast, colorectal, and prostate cancers at rates consistent with the general population. No clustering of specific cancer types occurred, suggesting random occurrence rather than drug-related causation.
How does the MHRA monitor Mounjaro cancer safety?
The MHRA uses the Yellow Card reporting scheme for continuous post-marketing surveillance of all medications including Mounjaro. Healthcare professionals and patients can report suspected side effects, and no cancer signals have emerged in UK real-world use.
Can losing weight with Mounjaro reduce my cancer risk?
Obesity is an established risk factor for thirteen types of cancer, and sustained weight loss may reduce long-term cancer risk. Mounjaro's average 20-22% body weight reduction in clinical trials addresses this underlying risk factor, potentially lowering lifetime cancer risk.
Are other weight loss injections safer than Mounjaro regarding cancer?
GLP-1 receptor agonists including semaglutide (Wegovy) and liraglutide (Saxenda) have similar cancer safety profiles with no increased risk in clinical trials. All GLP-1 treatments share the same precautionary thyroid cancer warning based on rodent studies, not human evidence.
Can Mounjaro cause cancer according to UK research?
Current UK and international studies have not established that Mounjaro causes cancer in humans. Tirzepatide, the active ingredient in Mounjaro, has been extensively reviewed by the MHRA and regulatory bodies, with ongoing post-market surveillance to monitor any long-term risks including cancer.
Is there a cancer warning for Mounjaro in the UK?
Mounjaro's UK patient information includes precautionary advice regarding thyroid tumours observed in animal studies, though human relevance remains uncertain. Cured Pharmacy ensures all patients are screened for personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 before prescribing.
Does Mounjaro increase cancer risk compared to other weight loss treatments?
There is no current evidence that Mounjaro increases cancer risk more than other GLP-1 or dual agonist medications approved in the UK. Cured Pharmacy prescribers conduct thorough medical assessments and discuss individual risk factors to ensure Mounjaro is appropriate and safe for each patient.
Should I avoid Mounjaro if I have a family history of cancer UK?
A general family history of cancer is not an automatic contraindication for Mounjaro use in the UK. However, specific family history of medullary thyroid carcinoma or MEN 2 syndrome means Mounjaro should not be used, and Cured Pharmacy clinicians will review your full medical and family history during consultation.
Where can I find UK safety data on Mounjaro and cancer?
UK safety data on Mounjaro is available through the MHRA Yellow Card scheme, the electronic Medicines Compendium, and published clinical trial results. Cured Pharmacy stays updated with the latest MHRA guidance and provides patients with current, evidence-based information during every prescribing consultation.
Can Mounjaro cause cancer in UK patients?
Current clinical evidence does not show that Mounjaro (tirzepatide) causes cancer in humans. The MHRA-approved prescribing information confirms Mounjaro has undergone rigorous safety testing, and Cured Pharmacy only dispenses medicines meeting UK regulatory standards for patient safety.
Has Mounjaro been linked to thyroid cancer UK cases?
Mounjaro carries a warning about thyroid C-cell tumours seen in animal studies, but no causal link has been established in humans. Cured Pharmacy pharmacists screen all patients for personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 before prescribing.
Are there any cancer warnings for Mounjaro in the UK?
Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome due to precautionary findings in rodent studies. Cured Pharmacy's UK-registered prescribers conduct thorough medical assessments to identify any contraindications before approving treatment.
Is Mounjaro safer than other weight loss injections regarding cancer risk UK?
Mounjaro belongs to the same GLP-1 receptor agonist class as Wegovy and Ozempic, which share similar precautionary thyroid warnings from animal data. All three medications are considered safe for use in the UK when prescribed appropriately, and Cured Pharmacy ensures comprehensive screening for all weight loss injection patients.
Should I stop taking Mounjaro if concerned about cancer UK?
If you have concerns about cancer risk while taking Mounjaro, contact Cured Pharmacy's clinical team for personalised advice rather than stopping abruptly. Our UK-registered pharmacists can review your medical history, discuss the latest safety evidence, and help you make an informed decision about continuing treatment.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 13 August 2026

Last updated on 13 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 13 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (13 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.